Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy

Early results show steroid-free remission, opening pathway into $13B global pet dental health market

VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy

SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 19, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer of low-dose oral interferon therapeutics, today announced compelling interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis ("FCGS"), a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class of immunotherapy in companion animals.

The randomized, controlled trial aims to enroll 30 cats, divided into high- and low-dose treatment groups, to assess pre- and post-treatment inflammation scores, corticosteroid usage, and safety. The focus is on chronic inflammatory diseases such as feline gingivostomatitis-an area where effective long-term treatments remain limited and largely reliant on steroids.

To date, three cats have completed treatment, with a fourth currently in progress. All cases have shown clear clinical improvements and strong tolerability:

• Case 1 (5-year-old cat, severe oral inflammation):

  • Inflammation score reduced from 19 to 17 (10.5% improvement)

  • Previous treatment with a French high-dose injectable interferon treatment was ineffective

  • Steroid dose successfully reduced from 0.8mg/kg/day to 0.5mg/kg/day with stable condition

• Case 2 (14-year-old cat, chronic inflammation):

  • Score reduced from 16 to 12.3 (23.1% improvement)

  • Steroid therapy was fully discontinued two months after treatment; condition remains stable

• Case 3 (index case):

  • Score reduced from 9 to 5 (44.4% improvement)

  • Steroids discontinued post-treatment; no relapse observed

No significant side effects were observed in any case. The results also suggest a steroid-sparing effect, which is critical for improving long-term outcomes in aging or chronically ill pets.